Navigation Links
Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
Date:4/17/2008

n the market for infected diabetic foot ulcers, we view this phase 2 program as a significant step towards treating and potentially preventing this highly serious and widely prevalent complication of diabetes."

About Infected Diabetic Foot Ulcers

According to the Centers for Disease Control and Prevention (CDC), the estimated incidence of diabetes in the US exceeds 1.5 million new cases annually, with an overall prevalence of 20.8 million people, or 7% of the US population. By 2030, the International Diabetes Federation predicts that the Global prevalence of diabetes will almost double from 193 million people (estimated in 2003) to 366 million.

An estimated 15% of patients with diabetes will develop a lower extremity ulcer during the course of their disease. According to a large prospective study, approximately 7% of diabetic patients with foot ulcers will require an amputation. Diabetic foot is the most common cause of nontraumatic lower extremity amputations in the US and Europe, with an average of 82,000 amputations per year in the US costing an estimated $1.6 billion annually. The estimated cost of foot ulcer care in the US ranges from $4,595 per ulcer episode to more than $28,000, for the 2 years post diagnosis. The total annual cost of foot ulcer care in the US has been estimated to be as high as $5 billion.

About Innocoll, Inc.

Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. It develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx(R) and Liquicoll(R). Innocoll 's lead product, Gentamicin Surgical Implant for the treatment and prevention of surgical site infections, is approved for sale in 49 countries in Europe, Latin America, Middle East, Africa and Asia and is marketed under the following trade names; COLLATAMP(R) G, COLLATAMP(R) EG, SULMYCIN(R)
'/>"/>

SOURCE Innocoll Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
2. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
3. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
5. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
6. ViroPharma Announces Discontinuation of HCV-796 Development
7. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
8. Free Prostate Cancer Seminar in Lake Ridge, VA: Dr. Charles Snuffy Myers Announces Vitamin D Clinical Trials
9. Phreesia Announces Clinical Initiative to Better Manage Symptoms of Parkinsons Disease
10. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
11. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  Aptuit LLC announces that Aptuit SSCI, ... , has enhanced its capabilities in the areas ... large molecules, including biologic drugs, metabolites, and polymers, ... mass spectrometer. In making the announcement, ... "The expanded large molecule capability enhances our early ...
(Date:8/21/2014)... Aug. 21, 2014  Vermillion, Inc. (NASDAQ: ... cancers and women,s health, has appointed Holly B. ... Markets. Ms. Bauzon has a proven track ... coverage for laboratory services companies. She has more than ... Inc., where she held the position of Director, Lab ...
(Date:8/21/2014)... 21, 2014  eRelevance Corporation ( www.erelevancecorp.com ), ... that it has completed integration with Nextech, a ... Surgery and Dermatology practices. "Integration allows ... healthcare practices using Nextech," stated Bob Fabbio ... information from the EMR we are able to ...
Breaking Medicine Technology:Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2eRelevance Corporation Integrates with Nextech Electronic Medical Records 2
... , FORT COLLINS, Colo., Dec. 14 Manchester Pharmaceuticals, ... (chenodiol tablets). On October 22, 2009, the US ... therapy for patients suffering from gallstones in whom surgery ... advanced age. , Chenodal prescriptions have started to be ...
... 14 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today ... the addition of Lt. Gen. Ronald R. Blanck, DO, U.S. ... Associates, a federal health services consulting firm based in Falls ... nine members. , Dr. Blanck began his military career in ...
Cached Medicine Technology:Manchester Announces Availability of Chenodal(TM) 2Oxygen Biotherapeutics, Inc. Expands Board of Directors 2
(Date:8/23/2014)... 23, 2014 A team of New York ... longer when preceded by surgery and delivered by an experienced ... new study. Click here to read it now . ... cases of mesothelioma patients who underwent hemithoracic (one ... dose to the shape of a tumor. Patients who ...
(Date:8/23/2014)... Board of Directors voted on Monday, August 18th to approve ... for commercial and industrial properties. This was accomplished with ... in Carmel, California. , This is a historical moment, ... the State of California has approved this technology for use ... can now be used as a sole source of water ...
(Date:8/23/2014)... TX (PRWEB) August 23, 2014 Youth ... of Texas. It’s no different in Houston, TX. Substance ... are falling victim to drug and alcohol dependency in ... are looking to beat substance abuse, but don’t know ... juvenile treatment facility can be a challenge because most ...
(Date:8/22/2014)... 23, 2014 The IT manager of ... hosting for several years. He has recently announced that ... hosting suppliers in 2014. , GoDaddy is a popular ... features and great hosting solutions at affordable rates. It ... for shared hosting plans depend on the length of ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 AWeber, ... services that currently helps more than 120,000 small ... caught the attention of Shane Michaels, prompting an investigative ... crucial element for any online marketing campaign, despite what ... in the marketing world,” reports Michaels. “AWeber is a ...
Breaking Medicine News(10 mins):Health News:New Study Links Hospital Experience and Prior Surgery with Mesothelioma Radiation Success, According to Surviving Mesothelioma 2Health News:Historical Moment in the Monterey Peninsula, Brings Drought Relief Solution to California, with the Help of EcoloBlue and AWG Technology 2Health News:New Houston Hotline Assisting Juveniles in Locating Dependable Rehabilitation Help 2Health News:AWeber: Review Exposes Affordable Provider of Opt-In Email Marketing Services 2
... Mass., Nov. 25 Gene Network Sciences, Inc.,(GNS) ... company, Fina,Technologies, Inc. (Fina) to leverage its proprietary ... new arena -- that of,quantitative financial trading and ... raw clinical and genomics data to identify drug,targets, ...
... Season , , ROSELAND, N.J., ... during the busy holiday season. Unfortunately many get drawn into buying ... At airports, it,s easy to wind up eating unhealthy foods ... a rush or have time to spend before a flight, you ...
... Pharmaceuticals, Inc.,(Nasdaq: ARNA ) announced today that the ... Health Care Conference on December 3, 2008 at 2:30,p.m. Eastern ... Hotel in,New York City. Jack Lief, Arena,s President and Chief ... including its clinical,development and discovery programs. , ...
... /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI), a Canadian ... of drug products delivered to and through the skin, ... and development subsidiary, has signed a research and development ... develops and markets skin care products. Financial details of ...
... 25 Hillenbrand, Inc.,(NYSE: HI ) -- ... United States,District Court in the Southern District of Texas ... denied in,two previously disclosed antitrust lawsuits against Batesville Casket ... As previously reported, a purported consumer ...
... WELLINGTON, Fla., Nov. 25 The Quantum Group,Inc. ... solutions provider for,the healthcare industry, announced today that ... approval and a Certificate,of Authority from the State ... RASI has been established to provide administrative ...
Cached Medicine News:Health News:Gene Network Sciences Announces Creation of Spin-off Entity Focused on Quantitative Finance and E-Commerce 2Health News:Gene Network Sciences Announces Creation of Spin-off Entity Focused on Quantitative Finance and E-Commerce 3Health News:Nutritionist Claudia Gonzalez Shares Tips for Eating Well On-the-Go During the Busy Holiday Rush 2Health News:Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference 2Health News:Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference 3Health News:Nuvo Research subsidiary signs collaboration agreement with Fortune Global 500 company 2Health News:Nuvo Research subsidiary signs collaboration agreement with Fortune Global 500 company 3Health News:Magistrate Judge Recommends Denial of Class Certification in Funeral Industry Antitrust Litigation 2Health News:The Quantum Group Announces State Approval of TPA Application for Subsidiary Company Renaissance Administrative Solutions, Inc. 2Health News:The Quantum Group Announces State Approval of TPA Application for Subsidiary Company Renaissance Administrative Solutions, Inc. 3Health News:The Quantum Group Announces State Approval of TPA Application for Subsidiary Company Renaissance Administrative Solutions, Inc. 4
Katena ophthalmic burr for polishing pterygiums, includes one round diamond burr and has an storage case....
Illuminated Trial Lens Set is an attractive set of trial lenses worked to a high standard of accuracy....
Trial Lens Sets....
... is the first ... to offer two kinds ... and taurine. Cleans, rinses, ... and conditions any soft ...
Medicine Products: